TY - JOUR
T1 - Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India
AU - Raj, Jeffrey Pradeep
AU - Gogtay, Nithya Jaideep
AU - Pandey, Avaneesh
AU - Kakkar, Ashish Kumar
AU - Shafiq, Nusrat
AU - Mekala, Padmaja
AU - Pingali, Usharani
AU - Raju, Arun Prasath
AU - Mallayasamy, Surulivelrajan
AU - Kshirsagar, Nilima Arun
N1 - Funding Information:
This study was conducted by the Indian Council of Medical Research (ICMR) Product Development Centers (PDCs), which were established in 2019 with a grant from the ICMR. No additional financial support was provided to the centers. The authors are thankful to scientists of Cliantha Research Ltd., Bodakdev, Ahmedabad, India, and its management for providing technical support and the infrastructure facility to carry out bioanalysis research work. The authors acknowledge the Technical Advisory Group members of the ICMR under the chairmanship of Dr V.P. Kamboj and Dr Urmila Thatte, retired Professor and Head, Department of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Mumbai, for their valuable suggestions and guidance during the development of the study protocol.
Publisher Copyright:
© 2022, The American College of Clinical Pharmacology.
PY - 2022/11
Y1 - 2022/11
N2 - Healthcare workers (HCWs) and frontline workers were recommended hydroxychloroquine (HCQ) 400 mg twice a day on day 1, followed by 400 mg once weekly for the next 7 weeks, as prophylaxis against COVID-19. There was limited information on the population pharmacokinetics (popPK) of HCQ in an Indian setting when administered for prophylaxis against COVID-19, and hence this study was proposed. It was a multicentric prospective study conducted at 3 sites in India wherein HCWs who were already on HCQ prophylaxis, who were about to start prophylaxis or who had stopped the prophylaxis for any reason were enrolled. Each participant gave 2 to 6 blood samples at different time points and whole-blood HCQ concentrations were assayed using liquid chromatography with tandem mass spectrometry (LC MS/MS). popPK analysis was performed using PUMAS 1.1.0. A total of N = 338 blood samples from N = 121 participants were included in the popPK analysis. A 2-compartment structural model with linear elimination was able to explain the observed data. Body weight was found to be a significant covariate influencing drug clearance. The final model was assessed using goodness-of-fit plots, a visual predictive check and a bootstrap, all of which confirmed that the model was appropriate. Simulations based on the current regimen showed that trough values were below the half-maximal effective concentration (EC50) of 0.7 μmol against COVID-19. A new weight-based dosage regimen was proposed to maintain the trough concentration above the EC50 threshold.
AB - Healthcare workers (HCWs) and frontline workers were recommended hydroxychloroquine (HCQ) 400 mg twice a day on day 1, followed by 400 mg once weekly for the next 7 weeks, as prophylaxis against COVID-19. There was limited information on the population pharmacokinetics (popPK) of HCQ in an Indian setting when administered for prophylaxis against COVID-19, and hence this study was proposed. It was a multicentric prospective study conducted at 3 sites in India wherein HCWs who were already on HCQ prophylaxis, who were about to start prophylaxis or who had stopped the prophylaxis for any reason were enrolled. Each participant gave 2 to 6 blood samples at different time points and whole-blood HCQ concentrations were assayed using liquid chromatography with tandem mass spectrometry (LC MS/MS). popPK analysis was performed using PUMAS 1.1.0. A total of N = 338 blood samples from N = 121 participants were included in the popPK analysis. A 2-compartment structural model with linear elimination was able to explain the observed data. Body weight was found to be a significant covariate influencing drug clearance. The final model was assessed using goodness-of-fit plots, a visual predictive check and a bootstrap, all of which confirmed that the model was appropriate. Simulations based on the current regimen showed that trough values were below the half-maximal effective concentration (EC50) of 0.7 μmol against COVID-19. A new weight-based dosage regimen was proposed to maintain the trough concentration above the EC50 threshold.
UR - http://www.scopus.com/inward/record.url?scp=85133069419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133069419&partnerID=8YFLogxK
U2 - 10.1002/jcph.2092
DO - 10.1002/jcph.2092
M3 - Article
C2 - 35656997
AN - SCOPUS:85133069419
SN - 0091-2700
VL - 62
SP - 1403
EP - 1411
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
IS - 11
ER -